Tetracycline to prevent epidermal growth factor receptor inhibitor‐induced skin rashes

BACKGROUND. Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention. METHODS. This placebo‐controlled, double‐blinded trial...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer 2008-08, Vol.113 (4), p.847-853
Hauptverfasser:	Jatoi, Aminah, Rowland, Kendrith, Sloan, Jeff A., Gross, Howard M., Fishkin, Paul A., Kahanic, Stephen P., Novotny, Paul J., Schaefer, Paul L., Johnson, David B., Tschetter, Loren K., Loprinzi, Charles L.
Format:	Artikel
Sprache:	eng
Schlagworte:	epidermal growth factor receptor inhibitor quality of life severity skin rash tetracycline
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!